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Intake of dietary flavonoids and risk of epithelial ovarian cancer1–4
Aedın Cassidy, Tianyi Huang, Megan S Rice, Eric B Rimm, and Shelley S Tworoger
ABSTRACT
Background: The impact of different dietary flavonoid subclasses
on risk of epithelial ovarian cancer is unclear, with limited previous
studies that have focused on only a few compounds.
Objective: We prospectively examined associations between habit-
ual flavonoid subclass intake and risk of ovarian cancer.
Design: We followed 171,940 Nurses’ Health Study and Nurses’ Health
Study II participants to examine associations between intakes of total
flavonoids and their subclasses (flavanones, flavonols, anthocyanins,
flavan-3-ols, flavones, and polymeric flavonoids) and risk of ovarian
cancer by using Cox proportional hazards models. Intake was calculated
from validated food-frequency questionnaires collected every 4 y.
Results: During 16–22 y of follow-up, 723 cases of ovarian cancer
were confirmed through medical records. In pooled multivariate-
adjusted analyses, total flavonoids were not statistically significantly
associated with ovarian cancer risk (HR for the top compared with
the bottom quintile: 0.85; 95% CI: 0.66, 1.09; P-trend = 0.17).
However, participants in the highest quintiles of flavonol and flava-
none intakes had modestly lower risk of ovarian cancer than did
participants in the lowest quintile, although the P-trend was not
significant [HRs: 0.76 (95% CI: 0.59, 0.98; P-trend = 0.11) and
0.79 (95% CI: 0.63,1.00; P-trend = 0.26), respectively]. The asso-
ciation for flavanone intake was stronger for serous invasive and
poorly differentiated tumors (comparable HR: 0.68; 95% CI: 0.50,
0.92; P-heterogeneity = 0.10, P-trend = 0.07) compared with non-
serous and less-aggressive tumors. Intakes of other subclasses were
not significantly associated with risk. In food-based analyses used to
compare subjects who consumed .1 and #1 cup black tea/d, the
HR was 0.68 (95% CI: 0.51, 0.90; P , 0.01).
Conclusions: Higher intakes of flavonols and flavanones as well as
black tea consumption may be associated with lower risk of ovarian
cancer. Additional prospective studies are required to confirm these
findings. Am J Clin Nutr 2014;100:1344–51.
INTRODUCTION
Epithelial ovarian cancer remains a highly lethal malignancy,
and to date, few modifiable risk factors have been established (1,
2). With respect to diet, early ecologic studies suggested that
a high plant-based diet that is rich in fruit and vegetables may be
related to decreased risk, (3–5) although subsequent case-control
and prospective studies have yielded inconsistent findings (6–
11). Plants contain bioactive constituents called flavonoids that
modulate key cellular signaling pathways and regulate multiple
cancer-inflammation pathways and epigenetic cofactors. These
compounds have the potential to exert chemopreventive effects
(12–14), suggesting that flavonoids might be specific compo-
nents in plants that could reduce ovarian cancer risk.
Flavonoidsarepresent inmanyfoodsandbeverages includingfruit,
vegetables, tea, andwine.Flavonoid subclasses commonlyconsumed
in the United States include flavanones, flavonols, anthocyanins,
flavan-3-ols, flavones, and polymeric flavonoids. Relatively few
studies have examined the association between these compounds and
ovarian cancer risk. Case-control studies generally have reported
inverseassociationsbetweenflavonolsandflavonesandriskofovarian
cancer (15–17). Our previous prospective analysis of 5 specific
compounds in these classes also observed suggestive inverse asso-
ciations (18). However, a subsequent prospective study, which ex-
amined associations of flavones and some flavonols across several
cancer sites, observed no associations with ovarian cancer (19).
Previous studies were limited by relatively small case numbers, and
because, until recently, food databases did not contain the compre-
hensive range of flavonoids present in the diet, no previous studies, to
our knowledge, have examined the full range of flavonoid subclasses
in relation to ovarian cancer risk. Therefore, we examined the asso-
ciation of 6 flavonoid subclasses, total flavonoid intake, and their
main food sourceswith risk of epithelial ovarian cancer in theNurses’
Health Study (NHS)5 andNurses’Health Study II (NHSII), including
an examination by tumor subtypes, with more than twice the number
of cases than in our previous analysis (18).
SUBJECTS AND METHODS
Study population
The NHS commenced in 1976 when 121,700 US women aged
30–55 y completed a mailed questionnaire about known and
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suspected risk factors for cancer and cardiovascular disease. In
1989, a younger cohort of 116,430 women aged 25–42 y were
enrolled in the NHSII by using similar questionnaires. Partici-
pants have completed follow-up questionnaires biennially, pro-
viding updated information on lifestyle factors and disease
diagnoses. Every 2–4 y, women receive semiquantitative food-
frequency questionnaires (FFQs) (20, 21). To maximize the
statistical power, we included participants who had answered at
least one FFQ since 1984 for NHS participants or 1991 for
NHSII participants. As a result, individuals entered the analysis
at the questionnaire cycle in which they completed their first
FFQ. Participants who reported a bilateral oophorectomy,
menopause as result of pelvic irradiation, or cancer other than
nonmelanoma skin cancer before study entry, did not complete
an FFQ during follow-up, or had implausible values for total
caloric intake (,500 or .3500 kcal/d) were excluded, which
resulted in the inclusion of 82,289 women from the NHS and
89,651 women from the NHSII for a total of 171,940 partici-
pants. The Institutional Review Board at Brigham and Women’s
Hospital reviewed and approved this study, and participants
provided implied consent by returning their questionnaires.
Outcome assessment
The outcome was incident epithelial ovarian cancer. We
collected information about new ovarian cancer diagnoses on
each biennial questionnaire. For 90% of reported cases as well as
deaths that were ovarian cancer identified through family
members, the US National Death Index, or the US Postal Service,
we obtained medical records related to the diagnosis. When
we were unable to obtain medical records, we linked to the
appropriate cancer registry to confirm the diagnosis. An estimated
98% of all deaths in the NHS and NHSII are captured through the
National Death Index (22, 23). A gynecologic pathologist blinded
to exposure status reviewed medical records to confirm the di-
agnosis and abstract stage, histology, and invasiveness.
Dietary assessment
Dietary intake data were assessed in 1984, 1986, and every 4 y
thereafter in the NHS. Similar FFQs were initially administered
in 1991 and subsequently every 4 y in the NHSII. A database for
the assessment of intakes of different flavonoid subclasses was
constructed as previously described (24) by using USDA data-
bases for the flavonoid and proanthocyanin contents of foods as
primary data sources (25, 26).
Briefly, intakes of individual compounds were calculated as
the sum of the consumption frequency of each food multiplied
by the content of the specific flavonoid for the specified portion
size. We derived intakes of the subclasses commonly consumed
in the US diet, specifically flavanones (eriodictyol, hesperetin,
and naringenin), anthocyanins (cyanidin, delphinidin, malvidin,
pelargonidin, petunidin, and peonidin), flavan-3-ols (catechins
and epicatachin), flavonols (quercetin, kaempferol, myricetin,
and isohamnetin), flavones (luteolin and apigenin), flavonoid
polymers (proanthocyanidins, theaflavins, and thearubigins), and
proanthocyanidins alone. Cumulative average intakes (energy
adjusted) were calculated for a given questionnaire cycle by
averaging the intake for current and preceding FFQs to assess
long-term flavonoid intake and minimize the within-person
variation; for questionnaire cycles without an FFQ, we used the
cumulative average exposure assessed through the previous cycle.
The validity and reproducibility of the FFQs have been reported
previously, and correlations between major dietary sources of
flavonoids, including fruit, vegetables, tea, and wine, measured by
diet records and the FFQs were 0.70, 0.50, 0.77, and 0.83, re-
spectively (27–29). We also conducted food-based analyses of the
following main sources of flavonols, proanthocyanidins, flava-
nones, and flavones: tea, onions, celery, apples, and citrus fruit
and juices.
Statistical analysis
Participants contributed person-time of follow-up from the
date of return of the first available FFQ to the date of any cancer
diagnosis, bilateral oophorectomy, menopause as a result of
pelvic irradiation, death, or end of follow-up (June 2010 for the
NHS and June 2011 for the NHSII). We used Cox proportional
hazard regression for time-varying covariates to estimate the HR
and 95% CI for flavonoid intake in relation to risk of ovarian
cancer with the lowest quintile of intake as the referent group.We
used a 4-y lag between exposure assessment and disease in-
cidence to address the issue that early symptoms of undiagnosed
ovarian cancer may alter habitual food intake. For example, we
used cumulative average intake from 1984 to 1990 as the ex-
posure for the follow-up period from 1994 to 1998 and cumu-
lative average intake from 1984 to 1994 for follow-up from 1998
to 2002. Because of relatively low within-individual correlations
over time in flavonoid intake, if a woman did not answer a
particular FFQ, she did not contribute person-time until she
answered a subsequent FFQ.
Analyses were conducted within each cohort separately and
pooled (stratifying by cohort) because no heterogeneity in as-
sociations was observed by using a random-effects meta-analysis
(30). To facilitate the comparison of results, common dietary
quintiles derived from the pooled distribution of both studies
were used. All analyses were stratified by age in months and the
calendar year of the current questionnaire cycle, and we further
controlled for menopausal status (premenopausal compared with
postmenopausal), the duration of oral contraceptive use (never
and ,1, 1–5, and .5 y), type (estrogen only, estrogen plus
progesterone, and other) and duration of postmenopausal hor-
mone (never and ,5, 5–10 and .10 y), parity (nulliparous and 1,
2, 3, and.3 children), history of tubal ligation (yes or no), history
of hysterectomy (yes or no), family history of breast or ovarian
cancer (yes or no), cumulative updated average total energy intake
(kcal/d, in quintiles), caffeine intake (mg/d, in quintiles), and
lactose intake (g/d, in quintiles). Flavonoid intakes were adjusted
for total energy intake by using the residual method (21).
In addition, we examined associations by histologic subtypes
(serous invasive and poorly differentiated cancers compared with
nonserous) and tumor aggressiveness [defined by rapidly fatal
(death #3 y of an ovarian cancer diagnosis) compared with less
aggressive (all others)] (31) by using competing risks Cox
models because there has been evidence that the cause of
ovarian cancer may differ by histologic subtype and aggres-
siveness (32). For the tumor-aggressiveness analysis, the end of
follow-up was June 2008 for the NHS and June 2009 for the
NHSII to ensure $3 y of follow-up after diagnosis (mortality
follow-up was updated through to 2012 for both cohorts). We
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also evaluated whether the association between flavonoid intake
and incidence of ovarian cancer differed by menopausal status at
diagnosis. All analyses were conducted with SAS software
(version 9; SAS Institute Inc). All P values were 2 sided.
RESULTS
During 1,139,897 person-years of follow-up in the NHS and
1,128,526 person-years of follow-up in the NHSII, 723 cases of
incident ovarian cancer were confirmed. At the midpoint of
follow-up, women with higher compared with lower total fla-
vonoid intakes were slightly older and had lower total energy and
lactose intakes (Table 1). The flavonoid polymer subclass con-
tributed most to total flavonoid intake (IQR: 95.4–274.7 mg/d),
whereas IQRs for flavonol and flavanone intakes ranged from
10.2 to 20.9 and 15.8 to 52.6 mg/d, respectively.
In pooled multivariate-adjusted analyses, total flavonoids were
not significantly associated with ovarian cancer risk (HR for top
compared with bottom quintiles: 0.85; 95% CI: 0.66, 1.09;
P-trend = 0.17) (Table 2). However, participants in the highest
quintiles of flavonol and flavanone intakes had modestly lower
risk of ovarian cancer than that of participants in the lowest
quintiles [HRs: 0.76 (95% CI: 0.59, 0.98; P-trend = 0.11) and
0.79 (95% CI: 0.63, 1.00; P-trend = 0.26), respectively]. Intakes
of other subclasses were not significantly associated with ovarian
cancer risk. We also examined the contribution of individual
constituents of flavonol and flavanone subclasses (see Supple-
mental Table 1 under “Supplemental data” in the online issue),
but none reached statistical significance. In stratified analysis, we
did not observe an interaction with menopausal status [HR for top
compared with bottom quintiles for flavonols: 0.71 (95% CI: 0.41,
1.20) in premenopausal women; 0.77 (95% CI: 0.58, 1.02) in
postmenopausal women; P-interaction = 0.59; HRs for top
compared with bottom quintiles for flavanones: 0.73 (95% CI:
0.43, 1.26) in premenopausal women; and 0.79 (95% CI: 0.60,
1.03) in postmenopausal women; P-interaction = 0.33]. We gen-
erally did not observe heterogeneity by cohort (data not shown).
We examined associations by histologic subtype by comparing
serous and poorly differentiated tumors (n = 442) with nonserous
tumors (n = 274). There was a suggestion that flavanones were
more-strongly associated with lower risk of serous invasive and
poorly differentiated tumors (HR for top compared with bottom
quintiles: 0.68; 95% CI: 0.50, 0.92) than risk of nonserous tu-
mors (HR for top compared with bottom quintiles: 1.04; 95% CI:
0.72, 1.50; P-heterogeneity = 0.10; Table 3). Apart from flavones
(data not shown), no heterogeneity in associations by subtype was
observed for other flavonoid subclasses (P-heterogeneity . 0.52).
In general, we did not observe different associations by tumor
TABLE 1
Age-standardized characteristics of the study population at follow-up midpoint by quintiles of total flavonoid intake in the NHS (1998) and the NHSII
(2001)1
NHS NHSII
Q1 Q3 Q5 Q1 Q3 Q5
Subjects (n) 10,035 10,024 10,027 11,877 11,901 11,887
Age (y) 63.3 6 7.12 64.4 6 7.0 64.6 6 7.3 46.1 6 4.6 46.5 6 4.6 47.1 6 4.5
History of tubal ligation (%) 22 21 20 26 22 23
History of hysterectomy (%) 22 23 22 9 9 9
Family history of breast cancer or ovarian cancer (%) 16 17 16 13 13 14
Parous (%) 95 95 95 83 82 81
No. of children in parous women 3.3 6 1.6 3.2 6 1.5 3.2 6 1.5 2.3 6 0.9 2.3 6 1.0 2.3 6 0.9
Oral contraceptive use (%) 49 49 48 86 85 85
Duration of oral contraceptive use (mo)3 52.5 6 47.7 50.9 6 46.7 49.7 6 45.6 69.8 6 60.1 66.9 6 59.1 68.0 6 60.8
Postmenopausal (%) 93 93 93 15 15 16
Estrogen-only PMH use (%)4 19 21 18 4 4 4
Duration of estrogen-only PMH use ( mo)3 90.0 6 77.8 91.3 6 80.8 87.5 6 78.0 1.7 6 2.0 2.6 6 3.1 2.1 6 1.8
Estrogen-progestin PMH use (%)4 31 34 31 53 54 55
Duration of estrogen-progestin PMH use (mo)3 58.0 6 43.5 59.8 6 43.3 60.5 6 43.0 3.0 6 2.6 2.8 6 2.3 2.7 6 2.3
Total energy intake (cal/d) 1658 6 526 1763 6 523 1679 6 518 1748 6 550 1854 6 534 1765 6 534
Caffeine (mg/d)5 237 6 236 190 6 195 224 6 185 244 6 234 213 6 204 245 6 193
Lactose (g/d)5 16.6 6 13.8 16.5 6 11.9 15.6 6 11.6 17.7 6 14.9 18.3 6 13.0 16.9 6 12.7
Flavonol (mg/d)5 10.2 6 6.2 15.1 6 6.8 29.6 6 13.3 9.7 6 5.9 14.8 6 6.9 30.6 6 14.0
Flavone (mg/d)5 1.2 6 0.8 2.5 6 1.2 2.8 6 1.9 1.0 6 0.6 2.1 6 1.1 2.4 6 1.7
Flavanone (mg/d)5 23.7 6 21.8 55.6 6 36.4 62.3 6 54.1 16.2 6 15.9 41.2 6 32.7 46.6 6 49.1
Flavan-3-ol (mg/d)5 9.3 6 5.0 19.9 6 8.3 117 6 87 9.1 6 4.9 20.3 6 8.3 129 6 95
Polymers (mg/d)5 55.6 6 22.4 126 6 32 465 6 278 59.9 6 20.7 135 6 29 511 6 305
Anthocyanidin (mg/d)5 5.8 6 5.0 14.7 6 9.3 23.0 6 27.0 5.7 6 4.7 15.1 6 9.4 24.8 6 35.0
Proanthocyanidin (mg/d)5 54.6 6 22.9 114 6 37 191 6 87 57.9 6 21.7 119 6 37 199 6 93
Flavan-3-ols and polymers (mg/d)5 58.1 6 23.1 122 6 36 264 6 112 60.6 6 21.6 128 6 35 280 6 122
Total flavonoids (mg/d)5 107 6 30 237 6 19 699 6 353 102 6 28 230 6 20 743 6 397
1NHS, Nurses’ Health Study; NHSII, Nurses’ Health Study II; PMH, postmenopausal hormone; Q, quintile.
2Mean 6 SD (all such values).
3 In ever users.
4 In postmenopausal women.
5 Intake adjusted for total energy by using the nutrient residual method.
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TABLE 2
Cohort-specific and pooled HRs (95% CIs) for the association between total flavonoid and subclass intakes and incident epithelial ovarian cancer in the NHS
and the NHSII1
Quintile of intakes2
1 2 3 4 5 P-trend
Total flavonoids (mg/d) 117.13 186.7 258.0 373.1 713.4 —
NHS
No. of cases/person-years 112/228,949 113/228,485 135/228,938 109/231,309 93/222,217 —
HR (95% CI) 1.00 (reference) 0.91 (0.70, 1.19) 1.06 (0.82, 1.36) 0.86 (0.66, 1.13) 0.83 (0.63, 1.10) 0.14
NHSII
No. of cases/person-years 26/224,873 30/225,249 29/224,471 47/221,993 29/231,940 —
HR (95% CI) 1.00 (reference) 1.11 (0.65, 1.89) 1.04 (0.61, 1.77) 1.72 (1.05, 2.79) 0.93 (0.54, 1.60) 0.80
Pooled HR (95% CI) 1.00 (reference) 0.96 (0.76, 1.21) 1.07 (0.85, 1.34) 1.03 (0.81, 1.30) 0.85 (0.66, 1.09) 0.17
Flavonols (mg/d) 7.4 11.0 14.4 19.2 30.2 —
NHS
No. of cases/person-years 130/261,685 125/243,249 111/228,293 117/214,986 79/191,684 —
HR (95% CI) 1.00 (reference) 0.92 (0.71, 1.18) 0.84 (0.65, 1.09) 0.91 (0.70, 1.19) 0.73 (0.55, 0.98) 0.05
NHSII
No. of cases/person-years 24/191,652 17/210,016 35/225,477 51/238,637 34/262,743 —
HR (95% CI) 1.00 (reference) 0.61 (0.33, 1.14) 1.13 (0.67, 1.91) 1.49 (0.91, 2.45) 0.86 (0.50, 1.47) 0.90
Pooled HR (95% CI) 1.00 (reference) 0.87 (0.69, 1.09) 0.90 (0.71, 1.14) 1.03 (0.82, 1.30) 0.76 (0.59, 0.98) 0.11
Flavones (mg/d) 0.7 1.2 1.6 2.2 3.2 —
NHS
No. of cases/person-years 77/174,817 103/195,302 109/224,593 137/260,856 136/284,329 —
HR (95% CI) 1.00 (reference) 1.08 (0.80, 1.45) 1.01 (0.75, 1.35) 1.04 (0.78, 1.38) 0.89 (0.67, 1.19) 0.24
NHSII
No. of cases/person-years 44/280,972 29/259,602 33/229,222 27/192,602 28/166,128 —
HR (95% CI) 1.00 (reference) 0.68 (0.42, 1.09) 0.81 (0.51, 1.28) 0.82 (0.50, 1.33) 0.90 (0.55, 1.45) 0.93
Pooled HR (95% CI) 1.00 (reference) 0.95 (0.74, 1.22) 0.94 (0.74, 1.21) 0.97 (0.76, 1.23) 0.87 (0.68, 1.11) 0.31
Flavanones (mg/d) 7.8 18.6 31.2 47.5 75.8 —
NHS
No. of cases/person-years 97/181,515 82/187,558 107/224,788 139/266,853 137/279,184 —
HR (95% CI) 1.00 (reference) 0.75 (0.56, 1.01) 0.82 (0.62, 1.08) 0.88 (0.68, 1.15) 0.75 (0.57, 0.97) 0.16
NHSII
No. of cases/person-years 40/273,465 33/267,747 32/229,213 31/185,730 25/172,370 —
HR (95% CI) 1.00 (reference) 0.86 (0.54, 1.36) 0.93 (0.58, 1.50) 1.11 (0.69, 1.79) 0.93 (0.56, 1.55) 0.86
Pooled HR (95% CI) 1.00 (reference) 0.78 (0.61, 1.01) 0.85 (0.67, 1.08) 0.93 (0.74, 1.17) 0.79 (0.63, 1.00) 0.26
Flavan-3-ols (mg/d) 9.3 16.9 28.2 54.2 133.7 —
NHS
No. of cases/person-years 111/234,555 122/223,801 122/228,573 114/231,532 93/221,436 —
HR (95% CI) 1.00 (reference) 1.07 (0.83, 1.39) 1.03 (0.80, 1.34) 0.99 (0.76, 1.30) 0.90 (0.68, 1.19) 0.25
NHSII
No. of cases/person-years 25/218,908 26/229,718 46/224,960 35/222,082 29/232,857 —
HR (95% CI) 1.00 (reference) 0.97 (0.56, 1.69) 1.63 (0.99, 2.67) 1.29 (0.76, 2.17) 0.95 (0.55, 1.65) 0.43
Pooled HR (95% CI) 1.00 (reference) 1.06 (0.84, 1.34) 1.16 (0.92, 1.45) 1.06 (0.83, 1.34) 0.91 (0.71, 1.16) 0.16
Polymers (mg/d) 61.4 106.2 156.3 240.7 496.5 —
NHS
No. of cases/person-years 122/255,573 130/227,280 116/218,260 105/222,406 89/216,378 —
HR (95% CI) 1.00 (reference) 1.08 (0.84, 1.39) 0.99 (0.76, 1.28) 0.91 (0.70, 1.18) 0.83 (0.63, 1.10) 0.08
NHSII
No. of cases/person-years 22/197,300 30/226,489 37/235,387 43/231,374 29/237,976 —
HR (95% CI) 1.00 (reference) 1.20 (0.68, 2.08) 1.34 (0.78, 2.29) 1.60 (0.95, 2.69) 0.97 (0.55, 1.72) 0.57
Pooled HR (95% CI) 1.00 (reference) 1.10 (0.88, 1.38) 1.05 (0.83, 1.33) 1.03 (0.82, 1.31) 0.85 (0.66, 1.09) 0.07
Anthocyanins (mg/d) 2.5 5.2 8.9 14.0 23.9 —
NHS
No. of cases/person-years 99/210,408 96/227,476 127/245,131 138/240,150 102/216,733 —
HR (95% CI) 1.00 (reference) 0.82 (0.62, 1.09) 1.00 (0.77, 1.31) 1.11 (0.85, 1.44) 0.85 (0.64, 1.13) 0.73
NHSII
No. of cases/person-years 33/244,670 34/226,342 25/208,143 23/213,040 46/236,331 —
HR (95% CI) 1.00 (reference) 1.07 (0.66, 1.73) 0.79 (0.46, 1.34) 0.72 (0.42, 1.24) 1.22 (0.77, 1.93) 0.40
Pooled HR (95% CI) 1.00 (reference) 0.87 (0.68, 1.12) 0.96 (0.76, 1.22) 1.03 (0.82, 1.31) 0.95 (0.75, 1.21) 0.85
(Continued)
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aggressiveness, although higher proanthocyanidin intake was asso-
ciated with suggestively lower risk of rapidly fatal tumors, but not
less-aggressive tumors (HR for top compared with bottom quintiles:
0.70; 95% CI: 0.48, 1.04), than risk of less-aggressive tumors (HR
for top compared with bottom quintile: 1.06; 95% CI: 0.78, 1.45;
P-heterogeneity = 0.04).
We conducted food-based analyses for main dietary sources of
flavonols and flavonols. Main dietary sources of flavonols were
black tea (31%), onions (20%), and apples (10%), whereas citrus
fruit (36%; 27% from orange intake) and juices (63%; 54% from
orange juice) were the main dietary sources for flavanones (Table
4). To examine associations with the main dietary source of
flavonols, we compared subjects who consumed .1 cup black
tea/d with those who rarely or never drank tea and observed
significantly lower risk of ovarian cancer (HR: 0.69; 95% CI:
0.52, 0.93; P-trend = 0.03) (Table 4). We also compared subjects
who drank .1 cup black tea/d with those who drank #1 cup/d and
observed similar inverse associations (HR: 0.68; 95% CI: 0.51, 0.90;
P , 0.01). For other main foods that contributed to intake (apple;
grapefruit and grapefruit juice; onion; and orange and orange juice),
we did not observe significant associations.
DISCUSSION
In this large prospective cohort study we observed that par-
ticipants who had the highest habitual intakes of flavonols and
flavanones had significantly lower risk of epithelial ovarian
cancer. Associations for flavanones were more strongly associ-
ated with lower risk of serous and poorly differentiated tumors,
a more-aggressive disease phenotype. Main sources of these
compounds include tea and citrus fruits or juice, foods and drinks
that are readily incorporated into the habitual diet, suggesting that
simple changes in food intake could have an impact on ovarian
cancer risk. To our knowledge, this is the only prospective study
TABLE 2 (Continued )
Quintile of intakes2
1 2 3 4 5 P-trend
Proanthocyanidins (mg/d) 54.0 83.0 108.6 139.4 196.8 —
NHS
No. of cases/person-years 126/253,021 117/236,742 110/229,082 122/218,161 87/202,890 —
HR (95% CI) 1.00 (reference) 0.94 (0.73, 1.22) 0.88 (0.68, 1.15) 1.00 (0.77, 1.29) 0.76 (0.58, 1.01) 0.10
NHSII
No. of cases/person-years 24/200,236 23/216,890 36/224,990 29/235,608 49/250,801 —
HR (95% CI) 1.00 (reference) 0.87 (0.49, 1.54) 1.25 (0.74, 2.11) 0.95 (0.55, 1.64) 1.45 (0.88, 2.38) 0.07
Pooled HR (95% CI) 1.00 (reference) 0.93 (0.74, 1.17) 0.95 (0.76, 1.20) 0.98 (0.78, 1.24) 0.92 (0.73, 1.16) 0.64
1 Stratified by age and calendar time and adjusted for menopausal status, duration of oral contraceptive use, parity, history of tubal ligation, history of
hysterectomy, duration of postmenopausal hormone use by type, family history of breast or ovarian cancer, quintiles of cumulative updated energy-adjusted
lactose intake and caffeine intake, and quintiles of cumulative updated total energy intake. Further stratified by cohort in the pooled analysis. Median values in each
quintile were used to test for a linear trend. Cox proportional hazards models were used for all analyses. NHS, Nurses’ Health Study; NHSII, Nurses’ Health Study II.
2Quintiles were based on the distribution from the pooled study population.
3Median (all such values).
TABLE 3
HRs (95% CIs) for the association between intakes of total flavonoids, flavonols, and flavanones and incident epithelial ovarian cancer by histologic subtype
and tumor aggressiveness in the NHS and NHSII1
Histologic subtypes (n = 723) Tumor aggressiveness (n = 668)
Serous and poorly
differentiated (n = 446) Nonserous (n = 277) P-heterogeneity Rapidly fatal (n = 261) Less aggressive (n = 407) P-heterogeneity
Total flavonoids 0.49
HR (95% CI) 0.82 (0.60, 1.13) 0.86 (0.58, 1.27) — 0.71 (0.47, 1.06) 0.88 (0.63, 1.22)
P-trend 0.22 0.32 0.98 0.09 0.28
Flavonols 0.78
HR (95% CI) 0.75 (0.54, 1.03) 0.70 (0.47, 1.03) — 0.70 (0.47, 1.05) 0.74 (0.53, 1.04)
P-trend 0.15 0.20 0.92 0.19 0.21
Flavanones 0.94
HR (95% CI) 0.68 (0.50, 0.92) 1.04 (0.72, 1.50) — 0.83 (0.57, 1.22) 0.77 (0.56, 1.05)
P-trend 0.07 0.53 0.10 0.49 0.33
1HRs for comparison of highest with lowest quintiles stratified by age, calendar time, and cohort and adjusted for the duration of oral contraceptive use,
parity, history of tubal ligation, history of hysterectomy, duration of postmenopausal hormone use by type, family history of breast or ovarian cancer, and
quintiles of energy-adjusted lactose, caffeine, and total energy intakes. Tumor aggressiveness was defined as rapidly fatal within 3 y of ovarian cancer
diagnosis. To allow $3 y postdiagnostic follow-up, the endpoint for rapidly fatal ovarian cancer was June 2008 for the NHS and June 2009 for the NHSII,
respectively. Cox proportional hazards models were used to estimate HRs, and median values in each quintile were used to test for a linear trend. A random-
effects meta-analysis method was used for the test of heterogeneity. NHS, Nurses’ Health Study; NHSII, Nurses’ Health Study II.
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to comprehensively examine the 6 major flavonoid subclasses
present in the diet with ovarian cancer risk and the first to in-
vestigate the impact of polymers and anthocyanins.
In the current study, we observed significantly lower risk of
high intakes of flavonols and flavanones only for women in the
top quintile (compared with the bottom quintile) of intakes. This
results may have been because the absolute range in intake across
the 3 middle quintiles compared with the lowest quintile was
relatively small (eg, 10 mg for flavonols and 33 mg for flava-
nones); the measurement error in these middle quintiles may have
obscured an association. Another possibility is that there was
a threshold effect. Previous data suggested that there may be
a threshold dose required for biological effects and low intakes
are unlikely to be bioactive (33). When we compared extreme
deciles of intake, subjects in the top decile had 29% (flavonols)
and 28% (flavanones) reductions in risk of ovarian cancer, which
suggested a continual dose-response at higher habitual intakes.
Results of this study were consistent with our earlier study that
evaluated several individual compounds present in the 2 flavonoid
subclasses flavonols and flavones (18, 19). In our previous pro-
spective study (n = 346 cases), we examined the only 5 flavonoid
constituents available in food-composition tables at the time
[3 flavonols (myricetin, kaempferol, and quercetin) and the fla-
vones (apigenin, luteolin)]. We observed significant inverse trends
for all 3 flavonols and luteolin, although after multivariate ad-
justment, only kaempferol and luteolin remained associated with
risk (18). In the Women’s Health Study, no associations were
observed for these flavonoids and ovarian cancer risk (19), al-
though the number of cases was small (n = 141). However, this
study did observe a small increase in risk of endometrial and
breast cancer when multivariable HRs between highest and lowest
quintiles of intake were compared (HRs: 1.15 and 1.03 for en-
dometrial and breast cancer, respectively) for total flavonoid in-
take (19). In a recent prospective study that integrated a wide
range of flavonoid subclasses, no associations between individual
flavonoid subclasses and breast cancer risk were observed (34).
Potential anticancer effects and molecular mechanism of
flavonols on ovarian cancer are not well understood, but
a number of flavonols, including quercetin, myricetin, and
kaempferol, are potential modulators of cellular signaling
pathways providing plausible mechanisms by which flavonols
could reduce cancer risk (35). Specifically, in vitro data have
suggested that quercetin can inhibit the proliferation of ovarian
cancer cell lines with inhibitory effects observed at exposures
observed in human diets (5 mg/mL). The mechanism appears to
be through the activation of autophagy, induction of apoptosis,
and inhibition of angiogenesis (36, 37). These laboratory data
have been supported by a recent animal study in which the
TABLE 4
Pooled HRs (95% CIs) for the association between intakes of flavonoid-rich food and incident epithelial ovarian cancer in
the NHS and NHSII1
Values P-trend
Frequency of servings ,1/wk 1/wk 2–6/wk 1/d .1/d
Tea
No. of cases 395 65 103 90 54 —
HR (95% CI) 1.00 (reference) 1.07 (0.82, 1.40) 1.02 (0.82, 1.28) 1.11 (0.87, 1.40) 0.69 (0.52, 0.93) 0.03
Frequency of servings ,1/mo 1–3/mo 1/wk 2–4/wk $5/wk —
Apple
No. of cases 96 181 136 198 97 —
HR (95% CI) 1.00 (reference) 0.93 (0.73, 1.20) 0.87 (0.67, 1.14) 0.99 (0.77, 1.27) 0.99 (0.74, 1.33) 0.52
Celery
No. of cases 163 210 167 135 43 —
HR (95% CI) 1.00 (reference) 0.96 (0.78, 1.18) 0.99 (0.79, 1.23) 1.02 (0.80, 1.29) 0.75 (0.53, 1.06) 0.21
Grapefruit/grape
fruit juice2
No. of cases 315 142 132 75 49 —
HR (95% CI) 1.00 (reference) 0.97 (0.80, 1.19) 1.09 (0.88, 1.35) 0.87 (0.67, 1.13) 0.95 (0.70, 1.30) 0.50
Onion
No. of cases 303 193 95 74 39 —
HR (95% CI) 1.00 (reference) 1.09 (0.91, 1.31) 0.93 (0.73, 1.17) 1.05 (0.81, 1.35) 0.99 (0.71, 1.40) 0.91
Orange
No. of cases 189 202 152 125 44 —
HR (95% CI) 1.00 (reference) 0.93 (0.76, 1.13) 1.11 (0.89, 1.37) 1.00 (0.79, 1.26) 0.88 (0.63, 1.23) 0.61
Frequency of servings ,1/mo 1–3/mo 1/wk 2–6/wk $1/d —
Orange juice
No. of cases 193 121 79 161 157 —
HR (95% CI) 1.00 (reference) 0.94 (0.75, 1.19) 0.82 (0.63, 1.07) 0.86 (0.70, 1.07) 0.83 (0.67, 1.04) 0.16
1 Stratified by age, calendar time, and cohort and adjusted for menopausal status, duration of oral contraceptive use,
parity, history of tubal ligation, history of hysterectomy, duration of postmenopausal hormone use by type, family history of
breast or ovarian cancer, quintiles of cumulative updated energy-adjusted lactose and caffeine intake, and quintiles of
cumulative updated total energy intake. Number of cases were slightly different by food because of missing values. Median
values in each category were used to test for a linear trend. Cox proportional hazards models were used for all analyses.
NHS, Nurses’ Health Study; NHSII, Nurses’ Health Study II.
2 Since 2002 in the NHS and 1999 in the NHSII, grapefruit and grapefruit juice were asked in one question.
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intravenous administration of high doses of quercetin (60 mg/
kg) to athymic nude mice with xenograft ovarian tumors in-
hibited angiogenesis and apoptosis in vivo (36). Furthermore,
kaempferol and the flavones (apigenin and luteolin) appeared
to inhibit cell growth at the 5-mmol/L amount in part via ac-
tions on vascular endothelial growth factor (38). Kaempferol at
supraphysiologic doses also may exert a chemopreventive ac-
tion through the blocking of phosphoinositide 3-kinase/protein
kinase B signaling pathways and the subsequent suppression
of activator protein-1 and nuclear transcription factor kB,
which are important transcription factors for neoplastic trans-
formation (35).
For flavanones, with the comparison of extreme quintiles of
intake, we observed 21% lower risk of ovarian cancer with higher
flavonone intake (median intake: 75.8 mg/d). To our knowledge,
this is the first population-based study to suggest a chemo-
preventive effect for flavanones on ovarian cancer risk. Although
potential anticancer effects for several flavanones, including
hesperetin (and its glycoside hesperidin) and naringenin, have
been described, including effects on inhibiting cell growth via
cell cycle arrest and p53-dependent apoptosis (39), the focus to
date has been on other cancer sites than the ovary. Although some
biological data support that certain flavan-3-ols can increase
apoptosis in ovarian cancer cell lines (40), we did not observe an
association with this subclass of flavonoids. Earlier versions of
our FFQs in the NHS did not capture all foods that may be
important sources of this specific flavonoid subclass, such as dark
chocolate, which potentially introduced a measurement error.
Available literature from both a molecular and epidemiologic
perspective has provided some evidence for a potential role for tea in
ovarian cancer prevention (40–42). In our confirmatory food-based
analysis of top sources of flavonoid subclasses, we showed sig-
nificantly lower risk of ovarian cancer with increased intake of
black tea. These data are in agreement with our earlier prospective
study (18) and support the observed beneficial effects of black tea
on ovarian cancer risk from other previous prospective studies (18,
43–46). In a recent meta-analysis (42), black tea consumption was
inversely associated with risk (combined HR: 0.73; 95% CI: 0.57,
0.93) in the prospective cohort studies.
Subtypes of ovarian carcinomas have different molecular,
pathologic, and clinical characteristics, which support the notion
that this histologic diversity may constitute several distinctive
entities rather than one single disease (47–49), and evidence has
suggested that some ovarian cancer risk-factor associations can
differ by histologic subtype (49). We observed a suggestively
stronger inverse association between higher flavanone intake and
risk of serous tumors. However, there was no association with
nonserous tumors. Because serous tumors tend to have poorer
outcomes, this outcome may have important implications for
prevention. However, we did not observe differences in the as-
sociation for rapidly fatal compared with less-aggressive tumors.
Strengths of our study included its prospective design, large
sample size with long-term follow-up, histologic subtype char-
acterization, repeated measures of dietary intake, comprehensive
assessment of the range of flavonoid subclasses present in the
habitual diet, and detailed data on ovarian cancer risk factors. Our
study also had some limitations.Althoughweadjusted for possible
confounders that are strongly associated with risk of ovarian
cancer, therewas still the possibility of residual confounding from
unmeasured factors.However, becauseof ourdetailed andupdated
adjustment for potential confounders, it was unlikely that these
would have accounted fully for the observed results. Also, mean
cumulative dietary flavonoid intakes were calculated from a da-
tabase developed from recent USDA databases with additional
input fromother sources (24); however,flavonoidcontentsoffoods
can vary depending on growth and processing conditions. Despite
this variation, these data allowed us to rank-order intakes and
compare high with low intakes in large population groups. Cor-
relationsbetween themajordietarysourcesofflavonoids (tea, fruit,
vegetables, and wine) and flavonoid intake have been determined
for our FFQ (27, 28), and in a recent flavonoid biomarker study,
similar correlations between the sum of 7 flavonoid biomarkers
measured in 24-h urine samples were observed (0.43–0.66) (50).
In conclusion, our data suggest that specific bioactive com-
pounds, including flavonols and flavanones, present in plant-based
foods may be associated with lower risk of ovarian cancer. In
particular, black tea intake was associated with lower risk, which
is already commonly consumed in many countries. Additional
prospective studies andmechanistic studies are required to confirm
these findings and determine whether the effect of diet varies with
different subtypes of ovarian cancer because of their different
molecular, pathological, and clinical characteristics.
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